摘要
针对很多无法手术治愈的中晚期肝细胞癌(hepatocellular carcinoma,HCC),肝动脉插管化疗栓塞术(transcatheter arterial chemoembolization,TACE)曾是重要的治疗手段之一。然而受限于不能完全杀灭肿瘤细胞、容易诱导肿瘤血管生成甚至转移等缺点,TACE并不能使患者的预后得到显著改善。近年来,分子靶向药物的出现为中晚期HCC患者的治疗提供了新选择。靶向治疗在HCC的治疗中表现出与TACE的良好协同性,能够弥补TACE肿瘤杀灭不全、术后易复发等不足,有效延长晚期HCC患者的生命周期。随着临床实验的不断推进,更多以多激酶抑制剂为首的靶向药物与TACE的联合治疗将会是中晚期HCC治疗的一个重要方向。本文聚焦近年来靶向药物联合TACE治疗HCC的发展情况,以期为临床中晚期HCC患者提供治疗策略。
Hepatocellular carcinomas(HCC) of intermediate and advanced stages that are not amenable to surgery are often treated with transcatheter arterial chemoembolization(TACE). It has been found that TACE has not considerably improved the prognosis of patients due to the problems of not being able to totally kill tumor cells and easily inducing tumor angiogenesis or even metastasis. When it comes to treating patients with advanced liver cancer, molecularly targeted medicines have emerged in recent years. In the treatment of HCC,targeted therapy has shown good synergy with TACE, which can compensate for TACE′s shortcomings, such as incomplete tumor killing and easy recurrence after surgery, and effectively prolong the life cycle of patients with advanced HCC. Combining multi-kinase inhibitors with TACE in the treatment of intermediate and advanced HCC will be an important direction in the future. Patients of HCC with intermediate or advanced stages may benefit from the newer targeted therapies that have recently been developed in conjunction with TACE, as we focused in this review.
作者
方绅哲
李宏
FANG Shenzhe;LI Hong(Medical School of Ningbo University,Ningbo 315211,China;Hepatopancreatobiliary Surgery Department of Medical Center,Ningbo Lihuili Hospital,Ningbo 315040,China)
出处
《生命的化学》
CAS
2022年第9期1729-1737,共9页
Chemistry of Life
基金
宁波市消化系统肿瘤临床医学研究中心项目(2019A21003)
宁波市公益类科技计划项目(2021S106)。
关键词
肝细胞癌
分子靶向治疗
肝动脉插管化疗栓塞术
hepatocellular carcinoma
molecular targeted therapy
transcatheter arterial chemoembolization
